Psychedelic Therapy Fails Without Proper Set and Setting

Most discussions about psychedelic therapy focus on the molecules. But what actually matters is what happens when the mental health system has already failed and why the medicine's biggest risk isn't the drug itself, but the absence of structure around it. Dr. Will Van Derveer, a psychiatrist with nearly 25 years of experience and co-founder of the Integrative Psychiatry Institute, explains how conventional care breaks down, why trauma often gets misdiagnosed as a disorder, and how the very quality that makes these medicines powerful, amplifying whatever is already inside, creates both their promise and their danger. This is for clinicians questioning their tools, patients who have cycled through treatments without relief, and anyone trying to understand why the regulatory chaos around psychedelics is not a bug but a feature of a system that does not know how to handle healing that works.

Why the Usual Approach Makes Things Worse

The conventional mental health system is not just failing. It is structurally designed to miss the root cause. Van Derveer points to the STAR-D trial, the largest publicly funded depression study ever conducted. After the first antidepressant trial, only 35% of patients responded. By the fourth trial, the chance of benefit dropped to 12%. The system responds by prescribing more medications, but the data shows this creates a compounding failure loop. Each failed trial makes the next less likely to work.

The hidden consequence is that patients are not treatment-resistant. They are root-cause-untreated. Van Derveer argues that what gets diagnosed as depression, anxiety, and even ADHD is often unresolved trauma expressing through different nervous system states. Someone stuck in a freeze response looks depressed. Someone stuck in hypervigilant fight-or-flight looks anxious or ADHD. The system treats the symptom cluster without asking what is driving it.

"The big problem in conventional care aside from the fact that the tools don't work so well for too many people... there's a more fundamental problem here which is that the way we diagnose conditions... there's no attention to the root cause." -- Dr. Will Van Derveer

Medicating symptoms without addressing root causes creates a carousel where patients cycle through treatments, each failure reinforcing the belief that they are broken. The system does not just fail to heal. It actively reinforces the trauma narrative.

Why Set and Setting Are Everything

Van Derveer's most important insight for anyone considering psychedelics is that these substances do not create experience. They amplify whatever is already inside. This is the opposite of psychiatric medications, which suppress symptoms. The implication is profound and easy to miss.

If you carry unresolved trauma and take psilocybin at a music festival without support, you are not rolling dice. You are amplifying a system primed for dysregulation. Van Derveer describes patients who have had explosive reemergence of traumatic material in unprotected settings, leading to panic, paranoia, and even legal consequences when they sought help from law enforcement while in an altered state.

The downstream effect is that a single bad experience can create more trauma than the original wound. This is why Van Derveer emphasizes that the medicine is not the treatment. The container is. The guide, the preparation, the integration. These are the active ingredients. The molecule is just the catalyst.

"You can harm people easily in the psychedelic session. How do we get people there in a few months of training?" -- Dr. Will Van Derveer

The competitive advantage here is counterintuitive. The more rigorous the preparation and the more conservative the approach, the better the outcomes. Van Derveer's patient Jane needed 10 MDMA sessions, more than triple the clinical trial protocol, because her trauma was so severe. The system that would have given her three sessions and called it done would have failed her. The system that gave her 10, with a guide who stayed with her through the process, allowed her to walk away from mental health care entirely.

The Long Game: Waiting for the Real Change

Van Derveer's own story reveals the delayed payoff that creates lasting advantage. After two patients died by suicide within days, he was devastated and ready to quit psychiatry. Instead, he followed Gabor Maté's advice to explore what the pain was about, and entered psychedelic therapy himself.

What emerged was not a memory he could access through talk therapy. It was a pre-verbal, body-level experience of abandonment from the first week of his life, being left alone in student housing after his mother was rushed back to the hospital post-birth. This was not in his narrative memory. It was in his nervous system.

Talk therapy and meditation, which Van Derveer had practiced extensively, could not reach this material. The psychedelic session, with a trained guide tracking his regression, unlocked something that years of conventional work had not touched. But this required patience, the willingness to have a terrifying experience of feeling like he had broken his mind before the healing emerged.

This is where discomfort now creates advantage later. Most people want the insight without the disorientation. Van Derveer's recommendation is not to believe everything you think after a psychedelic experience. The insights may be real, but the conviction can be premature. Integration, the work of grounding the experience into daily life, is where the actual change happens.

How the Regulatory System Gets in the Way

The regulatory landscape around psychedelics reveals a deeper systems problem. The FDA is designed to evaluate chemicals in isolation. But psychedelic therapy is not about the chemical. It is about the relationship between the patient, the guide, and the medicine in a prepared container.

When MDMA was presented to the FDA as psychotherapy assisted by MDMA, the agency did not know what to do with it. They are not in the business of regulating therapy. This created a cascade of consequences. The FDA denied approval in August 2024, citing concerns about how the therapy component was tracked. Other pharmaceutical companies observed this and adjusted their strategies, stripping out the therapy component to get a cleaner FDA review.

The tension is real. Medicalization makes these tools accessible but risks reducing them to pills. Keeping them outside the system preserves their depth but limits access to those who can afford to travel to Oregon, Colorado, or Mexico. Van Derveer's position is pragmatic: get things approved, save lives now, and figure out the therapy component within the room where the medicine is administered.

Over the next quarter, expect continued regulatory chaos. On a 12 to 18 month horizon, psilocybin likely gets federal approval by end of year, with MDMA potentially reapplying. The wildcard is ibogaine, which has remarkable anecdotal evidence for addiction treatment but carries cardiotoxicity risks that need more research.

What to Do Now

If you are considering psychedelic therapy, start with the preparation, not the medicine. Van Derveer recommends exploring EMDR, somatic experiencing, or IFS work first. These tools can resolve much of the material without the risks of psychedelics. Find a therapist trained in these modalities before seeking a guide.

When choosing a guide, prioritize word-of-mouth referrals over Google searches. Training matters enormously, and the field is full of well-intentioned people who can cause harm. This pays off in 12 to 18 months when you are working with someone who can actually track your regression and keep you safe.

Do not make sudden decisions after a psychedelic experience. The insights may be real, but the conviction can be premature. Van Derveer's rule is simple: do not believe everything you think. Schedule integration sessions with your guide or a therapist within 48 hours of any session.

For couples, consider ketamine-assisted therapy with one partner lying in the other's lap. This creates a window of fresh perception before habitual patterns reemerge. Over the next quarter, research providers who offer this modality specifically.

If you are a clinician, get trained in psychedelic therapy now. Van Derveer's institute has trained 10,000 professionals, and the demand will only increase as federal approvals come through. This pays off in 12 to 18 months when the regulatory landscape shifts.

For those with treatment-resistant depression, ketamine offers rapid relief but requires a plan for maintenance. The 70% response rate is real, but the benefits are fleeting without lifestyle changes. Combine ketamine treatment with diet, exercise, and therapy to build durable change.

Do not underestimate the power of conventional tools. Van Derveer is not anti-medication. He uses it as a short-term bridge to get patients stable enough to do the deeper work. Over the next quarter, audit your current treatment plan for what is actually moving the needle versus what is just maintaining the status quo.